OS Therapies Inc (OSTX)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.88+3.30%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OSTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Secure Biologics License Application approval in U.S. and Conditional Marketing Authorisations in U.K., Europe, and Australia for OST-HER2 by end of 2026.
Stated as a priority in 3 of last 3 quarters. Management expects regulatory approvals for OST-HER2 in the U.S., U.K., and Europe in the second half of 2026. Guidance and disclosures confirm ongoing regulatory interactions and hopeful approvals. The trajectory is delivering with regulatory milestones actively pursued.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Company expects to receive approvals in the U.S., U.K. and Europe for OST-HER2 in the prevention of delay of recurrent pulmonary metastatic osteosarcoma in the second half of 2026.”
“The Company is hopeful to gain regulatory approval for OST-HER2 in the UK in the second quarter of 2026.”
“The Company is hopeful to gain regulatory approval for OST-HER2 in the United States in the third quarter of 2026.”
Initiate global confirmatory Phase 3 trial for OST-HER2 in 2026 to support regulatory approvals and early market access.
Stated as a priority in 3 of last 3 quarters. Management plans to initiate the OST-HER2 Phase 3 confirmatory trial in 2026, with regulatory meetings and trial site activation in Australia underway. The trajectory is delivering with regulatory alignment and trial preparations progressing.
“Funding expected to support initiation of Phase 3 confirmatory trial, including planned activation of initial trial site in Australia.”
“Upcoming FDA Type C meeting to gain alignment on design of confirmatory Phase 3 study and MHRA meeting for same.”
“Confirmatory Phase 3 trial initiation planned for Q3 2026 in Australia to meet regulatory requirements.”
Raise capital and monetize UK tax credits to ensure sufficient cash runway to fund operations into 2027.
Stated as a priority in 3 of last 3 quarters. Management completed a $5.25 million direct offering and expects about $4 million in non-dilutive UK tax credits and VAT refunds, plus a $10 million line of credit, to fund operations into 2027. The trajectory is delivering with capital raises and funding sources secured.
“Company reiterates it expects to have sufficient cash and cash resources to provide runway into 2027.”
“Company secured $10 million line of credit supported by UK tax credits and received initial draw of $1.6 million.”
“Completed $5.25 million registered direct offering and expects $4 million in non-dilutive funds from UK subsidiary.”
Target peak European OST-HER2 osteosarcoma sales exceeding $300 million and over $50 million in sales in 2027 post-approval.
Stated as a priority in 2 of last 3 quarters. Management forecasts peak European OST-HER2 sales exceeding $300 million and over $50 million in 2027. These sales targets are linked to regulatory approvals and commercial launch preparations. The trajectory is aspirational with sales guidance provided but no current revenue reported.
“Company forecasts European peak OST-HER2 osteosarcoma sales exceeding $300 million with over $50 million in sales expected in 2027.”
“Following ATMP designation grant, peak European OST-HER2 sales expected to exceed $300 million.”
Progress clinical development of OST-504 for prostate cancer and OST-503 for non-small cell lung and pancreatic cancers.
Stated as a priority in 2 of last 3 quarters. Management is advancing OST-504 and OST-503 pipeline candidates with clinical data readouts and indication expansions planned. The trajectory shows ongoing development progress but no commercial revenue yet.
“Company anticipates reading out data from Phase 1b study of OST-504 in castration resistant prostate cancer in first half of 2026.”
“OST-503 Phase 2 non-small cell lung cancer candidate indications expanded to include pancreatic cancer.”
Over the trailing year it converted 0.55x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
32 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.